Overview

Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)

Status:
Completed
Trial end date:
2018-06-07
Target enrollment:
Participant gender:
Summary
This estimation study (no hypotheses) will evaluate the safety, tolerability, and efficacy of gefapixant (MK-7264) in Japanese adult participants with unexplained or refractory chronic cough.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.